Skip to main content
SpringerLink
Log in

Adalimumab as a cause of kidney injury in patients with Crohn’s disease

  • Clinical Insights
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Introduction

Adalimumab (ADM) is a recombinant human monoclonal antibody (anti-TNFα) used to treat inflammatory bowel diseases. It can cause kidney injury (KI).

Case diagnosis/treatment

We describe two pediatric patients with Crohn’s disease (CD) in whom ADM therapy was associated with kidney injury (KI). The drug was discontinued in both cases. For the first patient, changes were irreversible despite intensive glucocorticosteroid (GCS) therapy. For the second patient, discontinuation of ADM led to an improvement in kidney function.

Conclusions

Due to the risk of KI in patients undergoing ADM therapy, careful assessment of kidney function and early specialist referral are required. Timely withdrawal of ADM can significantly reduce kidney damage, but in some cases, the kidney damage can be irreversible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sandys V, Moloney B, Lane L, Qazi J, Doyle B, Barry M, Leavey S, Conlon P (2018) Granulomatous interstitial nephritis secondary to adalimumab therapy. Clin Kidney J 11:219–221. https://doi.org/10.1093/ckj/sfx104

    Article  PubMed  Google Scholar 

  2. Graziano F, Busè M, Cassata N, Lentini VL, Citrano M (2022) IgA nephropathy in a child: Crohn’s disease-associated or adalimumab induced? Curr Med Res Opin 38:139–143. https://doi.org/10.1080/03007995.2021.2015155

    Article  PubMed  Google Scholar 

  3. Chen TJ, Yang YF, Huang PH, Lin HH, Huang CC (2010) Permanent renal loss following tumor necrosis factor α antagonists for arthritis. Rheumatol Int 30:1077–1079. https://doi.org/10.1007/s00296-009-1016-2

    Article  PubMed  Google Scholar 

  4. Usui J, Salvatore SP, Yamagata K, Seshan SV (2023) Clinicopathologic spectrum of renal lesions following anti-TNF-α inhibitor therapy: a single center experience. Kidney360 4:363–373. https://doi.org/10.34067/KID.0000000000000063

    Article  Google Scholar 

  5. Tamura H (2023) IgA nephropathy associated with Crohn’s disease. World J Methodol 13:67–78. https://doi.org/10.5662/wjm.v13.i3.67

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Kidney Transplantation and Hypertension, The Children`s Memorial Health Institute, Warsaw, Poland

    Krzysztof Skoczyński, Jan Koziej, Łukasz Obrycki, Ryszard Grenda & Mieczysław Litwin

  2. Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, Warsaw, Poland

    Krzysztof Skoczyński & Jan Koziej

  3. Department of Pathology, The Children`s Memorial Health Institute, Warsaw, Poland

    Sylwia Szymańska

  4. Chair of Pediatric Nephrology, The Center of Continuing Medical Education, Warsaw, Poland

    Mieczysław Litwin

Authors
  1. Krzysztof Skoczyński
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Koziej
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sylwia Szymańska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Łukasz Obrycki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryszard Grenda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mieczysław Litwin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mieczysław Litwin.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Skoczyński, K., Koziej, J., Szymańska, S. et al. Adalimumab as a cause of kidney injury in patients with Crohn’s disease. Pediatr Nephrol (2024). https://doi.org/10.1007/s00467-024-06338-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00467-024-06338-0

Keywords

Search

Navigation